Trials / Completed
CompletedNCT02517736
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- University Hospital, Caen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma. The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib at a dose of 800 mg / day |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2015-01-13
- Completion
- 2015-01-13
- First posted
- 2015-08-07
- Last updated
- 2026-02-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02517736. Inclusion in this directory is not an endorsement.